Search Results

You are looking at 1 - 2 of 2 items for

  • Author: Gregory A. Vidal x
  • Refine by Access: All x
Clear All Modify Search
Full access

Selective Androgen Receptor Modulator in a Patient With Hormone-Positive Metastatic Breast Cancer

Namratha Vontela, Vamsi Koduri, Lee S. Schwartzberg, and Gregory A. Vidal

Androgen receptors (ARs) are highly coexpressed in estrogen receptor (ER)–positive breast cancers. Their role in breast tumorigenesis has been postulated, but the mechanism is not yet well-characterized. Steroidal androgens were previously used as an anticancer strategy but fell out of favor because of toxicity and the discovery of alternative therapies. Recent attempts to modulate androgen pathway signaling have focused on AR inhibitors. This report discusses a case using a well-tolerated selective AR modulator to treat a highly pretreated patient with ER-positive breast cancer, which resulted in a durable partial response.

Full access

CLO23-051: Real-World Use of Neratinib in Patients With HER2-Positive Early-Stage Breast Cancer Following Prior Ado-Trastuzumab Emtansine (T-DM1) or Dual HER2 Blockade With Pertuzumab Plus Trastuzumab

Kelly E. McCann, Nina Oestreicher, Christopher G. Rowan, and Gregory A. Vidal